Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Rhea-AI Summary

Soligenix (Nasdaq: SNGX) is hosting an exclusive live investor webinar on September 18, 2024, at 4:15 p.m. ET. CEO Christopher J. Schaber will discuss the company's development pipeline and upcoming milestones. Key highlights include:

1. HyBryte™ for cutaneous T-cell lymphoma (CTCL), with positive Phase 3 results and a follow-up study planned.

2. SGX302 for psoriasis, currently in Phase 2a trials.

3. SGX945 for Behçet's Disease, with a Phase 2a study starting this year.

4. ThermoVax® heat stable vaccine platform technology.

The company's pipeline targets a potential $2 billion in annual global sales. Investors can register for the free webinar and submit questions in advance.

Positive

• Positive Phase 3 results for HyBryte™ in treating CTCL, published in JAMA Dermatology
• HyBryte™ market potential estimated at $250 million
• SGX302 for psoriasis has a market potential exceeding $1 billion
• ThermoVax® platform has secured significant non-dilutive government funding
• Company's pipeline targets potential $2 billion in annual global sales

Negative

• Follow-up confirmatory Phase 3 study for HyBryte™ still required
• SGX302 and SGX945 are still in early clinical stages (Phase 2a)

PRINCETON, N.J., Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, Inc., will feature Soligenix President and Chief Executive Officer, Christopher J. Schaber, PhD, who will share insight into the Company's current development pipeline and upcoming milestones. The Company's pipeline includes several product candidates in advanced clinical stages, targeting a potential $2 billion in annual global sales. Notable among these is HyBryte™ (synthetic hypericin), a photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare chronic cancer, which has demonstrated positive results in a Phase 3 study published in JAMA Dermatology. The Company is now preparing to initiate a follow-up confirmatory Phase 3 study before yearend and recently reported positive data from a supportive comparability study; HyBryte's™ market potential is estimated at approximately $250 million. Additional promising assets include SGX302, aimed at treating psoriasis, currently in a Phase 2a trial with a market potential exceeding $1 billion; and SGX945 for Behçet's Disease, with a Phase 2a study set to begin later this year as well. Soligenix's pipeline also includes a Public Health Solutions business segment, highlighted by its heat stable vaccine platform technology, ThermoVax^®, which has previously secured significant non-dilutive government funding to support its vaccine development programs.

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_dBh5VINQT2qxkVjPQ1HxVQ#/registration.

Questions may be pre-submitted to SNGX@redchip.com or online during the live event.

About Soligenix

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behçet's Disease.

Our Public Health Solutions business segment includes development programs for RiVax^®, our ricin toxin vaccine candidate, as well as our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax™, our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax^®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

For further information regarding Soligenix, Inc., please visit the Company's website at https://www.soligenix.com and follow us on LinkedIn and Twitter at @Soligenix_Inc.

This press release may contain forward-looking statements that reflect Soligenix's current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations, clinical trial enrollment, the expected timing for closing the offering described herein and the intended use of proceeds therefrom. Statements that are not historical facts, such as "anticipates," "estimates," "believes," "hopes," "intends," "plans," "expects," "goal," "may," "suggest," "will," "potential," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements, and include the expected amount and use of proceeds from the offering and the expected closing date of the offering. Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize products based on its technologies, particularly in light of the significant uncertainty inherent in developing therapeutics and vaccines against bioterror threats, conducting preclinical and clinical trials of therapeutics and vaccines, obtaining regulatory approvals and manufacturing therapeutics and vaccines, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further funding to support product development and commercialization efforts, including grants and awards, maintain its existing grants which are subject to performance requirements, enter into any biodefense procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will not negatively affect its business, or that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program. In addition, there can be no assurance as to the timing or success of any of its clinical/preclinical trials. Despite the statistically significant result achieved in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma, there can be no assurance that the second HyBryte™ (SGX301) Phase 3 clinical trial will be successful or that a marketing authorization from the FDA or EMA will be granted. Additionally, although the EMA has agreed to the key design components of the second HyBryte™ (SGX301) Phase 3 clinical trial, no assurance can be given that the Company will be able to modify the development path to adequately address the FDA's concerns or that the FDA will not require a longer duration comparative study. Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Further, there can be no assurance that RiVax^® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales of PRVs will be indicative of any potential sales price for a PRV for RiVax^®. Also, no assurance can be provided that the Company will receive or continue to receive non-dilutive government funding from grants and contracts that have been or may be awarded or for which the Company will apply in the future. These and other risk factors are described from time to time in filings with the Securities and Exchange Commission (the "SEC"), including, but not limited to, Soligenix's reports on Forms 10-Q and 10-K. Unless required by law, Soligenix assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/join-soligenixs-exclusive-live-investor-webinar-and-qa-session-on-september-18-2024-302248438.html

SOURCE SOLIGENIX, INC.

FAQ

When is Soligenix (SNGX) hosting its investor webinar?

Soligenix (SNGX) is hosting its investor webinar on September 18, 2024, at 4:15 p.m. ET.

What is the market potential for Soligenix's (SNGX) HyBryte™ product?

The market potential for Soligenix's (SNGX) HyBryte™ product is estimated at approximately $250 million.

What is the total potential annual global sales target for Soligenix's (SNGX) pipeline?

Soligenix's (SNGX) pipeline targets a potential $2 billion in annual global sales.

Which Soligenix (SNGX) product has shown positive results in a Phase 3 study?

HyBryte™ (synthetic hypericin), Soligenix's (SNGX) photodynamic therapy for cutaneous T-cell lymphoma (CTCL), has shown positive results in a Phase 3 study.